LENZ Therapeutics (NASDAQ:LENZ) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of LENZ Therapeutics (NASDAQ:LENZ) from a sell rating to a hold rating in a research note issued to investors on Sunday.

LENZ has been the subject of several other reports. HC Wainwright restated a “buy” rating on shares of LENZ Therapeutics in a research note on Monday, December 15th. Zacks Research downgraded LENZ Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LENZ Therapeutics in a research report on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, LENZ Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.40.

LENZ Therapeutics Stock Performance

LENZ stock opened at $13.15 on Friday. LENZ Therapeutics has a one year low of $11.48 and a one year high of $50.40. The firm has a market cap of $411.46 million, a price-to-earnings ratio of -6.23 and a beta of 0.52. The firm has a 50-day simple moving average of $15.70 and a two-hundred day simple moving average of $27.41.

Hedge Funds Weigh In On LENZ Therapeutics

Hedge funds have recently made changes to their positions in the company. Quarry LP acquired a new stake in LENZ Therapeutics during the 3rd quarter worth about $27,000. Bfsg LLC acquired a new stake in shares of LENZ Therapeutics during the third quarter worth about $30,000. Osaic Holdings Inc. lifted its holdings in shares of LENZ Therapeutics by 2,146.2% during the second quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock worth $34,000 after purchasing an additional 1,116 shares during the period. Tower Research Capital LLC TRC boosted its position in LENZ Therapeutics by 51.4% in the second quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock valued at $41,000 after buying an additional 477 shares during the last quarter. Finally, SBI Securities Co. Ltd. increased its holdings in LENZ Therapeutics by 9,235.3% in the 3rd quarter. SBI Securities Co. Ltd. now owns 1,587 shares of the company’s stock worth $74,000 after buying an additional 1,570 shares during the period. 54.32% of the stock is owned by institutional investors and hedge funds.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.